KOSDAQ - Delayed Quote KRW

ALTEOGEN Inc. (196170.KQ)

317,500.00

-13,500.00

(-4.08%)

At close: 3:30:23 PM GMT+9

AstraZeneca and Alteogen agree on ALT-B4 platform tech

AstraZeneca will obtain worldwide rights for using ALT-B4.

Pharmaceutical Technology last month

AZN

196170.KQ
-4.08%
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.

Zacks last month

AZN

196170.KQ
-4.08%

BMRN
Eventful Monday For AstraZeneca - What's Going On?

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and safety of eneboparatide in adults with chronic hypoparathyroidism. The study showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance at 24 weeks in adults with chronic hypoparathyroidism (HypoPT) compared to placebo. The primary endpoint is a composite of norma

Benzinga last month

AZN

196170.KQ
-4.08%
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a subcutaneous version of ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and commercialized b

PR Newswire 6 months ago

DSKYF

DSNKY

196170.KQ
-4.08%
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

Alteogen Inc. (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA) for Tergase® (recombinant hyaluronidase).

PR Newswire 10 months ago

196170.KQ
-4.08%

196170.KS
Altos Biologics Files Approval of Aflibercept Biosimilar

Alteogen Inc. (KOSDAQ: 196170) announced on July 1st that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for an aflibercept biosimilar ALT-L9, developed by Alteogen.

PR Newswire 10 months ago

196170.KQ
-4.08%

196170.KS

Performance Overview

Return	196170.KQ	KOSPI Composite Index (^KS11)
YTD	+2.58%	+9.48%
1-Year	+78.37%	-4.58%
3-Year	+666.60%	+1.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ALTEOGEN Inc. (196170.KQ)

AstraZeneca and Alteogen agree on ALT-B4 platform tech

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

Eventful Monday For AstraZeneca - What's Going On?

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

Altos Biologics Files Approval of Aflibercept Biosimilar

Performance Overview